Literature DB >> 11395595

An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.

H Asakura1, Y Ontachi, T Mizutani, M Kato, M Saito, I Kumabashiri, E Morishita, M Yamazaki, K Aoshima, S Nakao.   

Abstract

OBJECTIVES: To investigate the relationship between fibrinolytic enhancement and the development of multiple organ failure (MOF) in disseminated intravascular coagulation (DIC). To detect the useful prognostic index for outcome in DIC.
DESIGN: Case-control study.
SETTING: A department of internal medicine in a university hospital, a clinical division for diagnosis and treatment, mainly of respiratory diseases, hematologic diseases, DIC, and other diseases requiring critical care medicine. PATIENTS: A total of 69 DIC patients, 31 with MOF.
INTERVENTIONS: None. MEASUREMENT AND MAIN
RESULTS: The DIC patients with MOF had more elevated levels of tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor antigen (PAI), and more depressed levels of plasmin-alpha2 plasmin inhibitor complex (PIC) and fibrin/fibrinogen degradation products than those without MOF, although no significant difference in thrombin-antithrombin complex (TAT) levels was observed. A fibrinolytic enhancement (shown by PIC) was parallel to an activation of blood coagulation (shown by TAT) in DIC patients without MOF, although no such fibrinolytic enhancement was provoked even by much activation of blood coagulation in DIC patients with MOF. Whereas all the patients without MOF were restored from DIC, 14 of 31 patients with MOF were unable to be restored from DIC and died. A significant increase in plasma levels of t-PA and PAI under the condition of sustained hemostatic activation was observed in the patients who died.
CONCLUSION: Enhanced fibrinolysis was considered to be the important defense mechanism in preventing the development of MOF in DIC. The increases in plasma levels of t-PA and PAI were poor prognostic markers in DIC. Further careful study may be useful to clarify whether the fibrinolytic therapy is beneficial in clinical DIC patients with MOF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395595     DOI: 10.1097/00003246-200106000-00015

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  17 in total

1.  Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.

Authors:  Seiji Madoiwa; Shin Nunomiya; Tomoko Ono; Yuichi Shintani; Tsukasa Ohmori; Jun Mimuro; Yoichi Sakata
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

2.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

3.  Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Michael P Chapman; Theresa L Chin; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2014-12       Impact factor: 3.313

4.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

5.  Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study.

Authors:  Sisse Rye Ostrowski; Nicolai Haase; Rasmus Beier Müller; Morten Hylander Møller; Frank Christian Pott; Anders Perner; Pär Ingemar Johansson
Journal:  Crit Care       Date:  2015-04-24       Impact factor: 9.097

Review 6.  Classifying types of disseminated intravascular coagulation: clinical and animal models.

Authors:  Hidesaku Asakura
Journal:  J Intensive Care       Date:  2014-03-06

Review 7.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis.

Authors:  Hidesaku Asakura; Hoyu Takahashi; Toshimasa Uchiyama; Yutaka Eguchi; Kohji Okamoto; Kazuo Kawasugi; Seiji Madoiwa; Hideo Wada
Journal:  Thromb J       Date:  2016-09-28

8.  Circadian Variation of Plasminogen-Activator-Inhibitor-1 Levels in Children with Meningococcal Sepsis.

Authors:  Navin P Boeddha; Gertjan J Driessen; Marjon H Cnossen; Jan A Hazelzet; Marieke Emonts
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

9.  Modern Management of Bleeding, Clotting, and Coagulopathy in Trauma Patients: What Is the Role of Viscoelastic Assays?

Authors:  Sanjeev Dhara; Ernest E Moore; Michael B Yaffe; Hunter B Moore; Christopher D Barrett
Journal:  Curr Trauma Rep       Date:  2020-01-23

10.  Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels.

Authors:  Runzhen Zhao; Gibran Ali; Hong-Guang Nie; Yongchang Chang; Deepa Bhattarai; Xuefeng Su; Xiaoli Zhao; Michael A Matthay; Hong-Long Ji
Journal:  Br J Pharmacol       Date:  2020-05-11       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.